Home » Stocks » VRAY

ViewRay, Inc. (VRAY)

Stock Price: $4.36 USD -0.12 (-2.68%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $4.36 +0.00 (0.02%) Feb 26, 5:35 PM
Market Cap 699.15M
Revenue (ttm) 55.03M
Net Income (ttm) -117.02M
Shares Out 148.04M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $4.36
Previous Close $4.48
Change ($) -0.12
Change (%) -2.68%
Day's Open 4.50
Day's Range 4.36 - 4.74
Day's Volume 1,169,613
52-Week Range 1.11 - 7.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 month ago

A big investor sells out of the company.

PRNewsWire - 1 month ago

STOCKHOLM, Jan. 22, 2021 /PRNewswire/ -- Elekta AB (EKTA-B.ST) announced today that it has sold its 7.3 percent of the outstanding common stock (11,501,597 shares) in ViewRay, Inc. (Nasdaq:VRA...

PRNewsWire - 1 month ago

CLEVELAND, Jan. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in a fireside chat at the B. Riley Oncolo...

The Motley Fool - 1 month ago

The company announced the pricing of a public offering of common stock.

PRNewsWire - 1 month ago

CLEVELAND, Jan. 7, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer pati...

PRNewsWire - 1 month ago

CLEVELAND, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer pati...

PRNewsWire - 1 month ago

CLEVELAND, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer pati...

PRNewsWire - 1 month ago

CLEVELAND, Ohio, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2020. The prelimin...

PRNewsWire - 2 months ago

CLEVELAND, Dec. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. Scott Drake, President and CEO, is...

PRNewsWire - 2 months ago

CLEVELAND, Dec. 22, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Seoul National University Hospital (SNUH), a leading healthcare facility in Sout...

PRNewsWire - 2 months ago

CLEVELAND, Dec. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Catharina Hospital in Eindhoven, Netherlands, also known as Catharina Ziekenhuis, has purchased a MRI...

PRNewsWire - 3 months ago

CLEVELAND, Nov. 12, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has treated one thousand pa...

PRNewsWire - 3 months ago

CLEVELAND, Nov. 10, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Universitair Ziekenhuis Brussels has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-...

Seeking Alpha - 3 months ago

ViewRay, Inc. (VRAY) CEO Scott Drake on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

ViewRay (VRAY) delivered earnings and revenue surprises of -11.76% and 13.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 3 months ago

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

CLEVELAND, Oct. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® Linac MRI-guided radiation therapy system will be featured at the 2020 Annual ...

PRNewsWire - 4 months ago

CLEVELAND, Oct. 14, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the Louis Stokes Cleveland VA Medical Center in Cleveland, Ohio has purchased the MRIdian® Linac MRI-...

Zacks Investment Research - 4 months ago

ViewRay (VRAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

PRNewsWire - 5 months ago

CLEVELAND, Sept. 24, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Chungnam National University Sejong Hospital in Sejong, South Korea has begun patient treatments wit...

PRNewsWire - 5 months ago

CLEVELAND, Sept. 4, 2020 /PRNewswire/ -- ViewRay, Inc.

PRNewsWire - 5 months ago

CLEVELAND, Sept. 1, 2020 /PRNewswire/ -- ViewRay, Inc.

PRNewsWire - 6 months ago

CLEVELAND, Aug. 13, 2020 /PRNewswire/ -- ViewRay, Inc.

PRNewsWire - 6 months ago

CLEVELAND, Aug. 5, 2020 /PRNewswire/ -- ViewRay, Inc.

Seeking Alpha - 6 months ago

ViewRay's (VRAY) CEO Scott Drake on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

ViewRay (VRAY) delivered earnings and revenue surprises of -12.50% and 144.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 6 months ago

CLEVELAND, July 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020.

Zacks Investment Research - 7 months ago

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

PRNewsWire - 7 months ago

CLEVELAND, July 13, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2020 financial results. ViewRay will hold a conferen...

Zacks Investment Research - 8 months ago

Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.

Other stocks mentioned: CLW, CMC, DOMO, MNTA
Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for June 23rd

Other stocks mentioned: HEAR, SNBR, ZUO
PRNewsWire - 8 months ago

CLEVELAND, June 3, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today grants of stock options and restricted stock units to Zach Stassen, Chief Financial Officer for the company...

PRNewsWire - 9 months ago

CLEVELAND, May 27, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Providence Portland Medical Center in Portland, Oregon has begun patient treatments with the MRIdian® ...

Seeking Alpha - 9 months ago

ViewRay's (VRAY) CEO Scott Drake on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

ViewRay (VRAY) delivered earnings and revenue surprises of 0.00% and 14.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.

Other stocks mentioned: CHE, DXCM, LLY, SAGE
Seeking Alpha - 11 months ago

ViewRay's Inc.'s (VRAY) CEO Scott Drake on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

ViewRay (VRAY) delivered earnings and revenue surprises of -24.00% and -3.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Shares plunge after the company announces preliminary quarterly results that came up short.

The Motley Fool - 1 year ago

Find out how strategic moves helped a couple of these stocks.

Other stocks mentioned: BOLD, LE
The Motley Fool - 1 year ago

Shares jump after the company announces a pair of collaborations and a capital raise. Here are the key details.

Zacks Investment Research - 1 year ago

ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

ViewRay's (VRAY) CEO Scott Drake on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

ViewRay (VRAY) delivered earnings and revenue surprises of 22.22% and 0.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Iris - 1 year ago

Written by: Craig Adeyanju | FinScreener Penny stocks, on the surface, look attractive because they generally have prices under $5. However, many penny stocks belong in that category for a rea...

Other stocks mentioned: GERN, NBEV, SENS
The Motley Fool - 1 year ago

Shares rally after management gives investors a sneak peek at its third-quarter results.

About VRAY

ViewRay designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government instit... [Read more...]

Industry
Medical Devices
Founded
2004
CEO
Scott William Drake
Employees
309
Stock Exchange
NASDAQ
Ticker Symbol
VRAY
Full Company Profile

Financial Performance

In 2019, ViewRay's revenue was $87.78 million, an increase of 8.42% compared to the previous year's $80.96 million. Losses were -$120.20 million, 57.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ViewRay stock is "Buy." The 12-month stock price forecast is 5.88, which is an increase of 34.86% from the latest price.

Price Target
$5.88
(34.86% upside)
Analyst Consensus: Buy